The aim of the study was to evaluate the relationship of the atherosclerotic lesions in the carotid arteries expressed as the CCA-IMT and selected biochemical parameters associated with bone and mineral metabolism (fetuin A, osteocalcin, FGF-23, osteopontin, osteoprotegerin) with reference to classic atherosclerotic risk factors in patients on peritoneal dialysis.
PATIENTs ANd mEThOds
The study group consisted of 67 patients with chronic kidney disease (CKD) (36 men and 31 women), aged 53 ±13 years (range, 19-75 years), and treated with peritoneal dialysis for 30 ±24 months (range, 4-100 months). Patients were included consecutively during 6 months. The inclusion criteria were as follows: age >18 years, continuous ambulatory peritoneal dialysis or automatic peritoneal dialysis, stable clinical course for at least 2 months before being included into the study, and a negative history of neoplastic diseases. The informed consent was obtained from each patient. The study protocol was approved by an institutional ethics committee.
The CCA-IMT was measured by a single investigator according to the current guidelines. It was visualized in the B presentation using Acuson 128/10 XP the linear 5/7 MHz head. Morning fasting blood samples were obtained during routine control examinations.
The following routine laboratory tests were performed in the Diagnostic Department, University Hospital: peripheral blood cell count, serum lipid levels (total cholesterol, high-and low-density lipoprotein, triglycerides), calcium, phosphorus, iPTH, and alkaline phosphatase. The serum concentrations of selected bone metabolism proteins were assessed using the commercially available enzyme-linked immunosorbent assay kits, including fetuin A (Human Fetuin A Elisa Kit, Epitope Diagnostics, United States), osteocalcin (METRA, Germany), osteoprotegerin (Human Osteoprotegerin Elisa Kit, Biomedica, Wien, Austria), osteopontin (Quantikine Human Osteopontin Elisa kit, R&D Systems, United Kingdom), and FGF-23 (Human FGF-23 Elisa kit, Immutopics, United States). The serum concentration of C-reactive protein (CRP) was determined by an immunonephelometric assay using Nephelometer BNII (Simens, Heathcare Diagnostics, Germany). The reference ranges for laboratory tests are presented in TAbLE 1 .
Continuous variables were assessed for normality by the Kolmogorov-Smirnov test. Means ± standard deviations are shown for normally distributed variables and medians (interquartile ranges) for nonnormal distributions. The Spearman coefficient was used to assess correlations between continuous variables. A multiple linear regression was applied to assess the effect of multiple variables on the CCA-IMT; right-skewed variables were log-transformed before the analysis. Partial correlation coefficients and P value were reported for each independent variable. Differences
In these patients, deposits surround inflammatory cell infiltrations, lipoproteins, and protein bone matrix in the areas of vascular and valvular calcifications. 3, [8] [9] [10] In the last decades, novel markers emerged that play an important role in the development of soft tissue calcifications. These include inhibitors of extraosseous calcification (such as fetuin A), multifunctional proteins (such as osteoprotegerin and osteopontin), and bone parameters (such as osteocalcin and fibroblast growth factor-23 ). [11] [12] [13] [14] Osteoprotegerin is a key cytokine that belongs to the tumor necrosis factor receptor superfamily and has a wide spectrum of pleiotropic effects on bone metabolism and endocrine function. 15 It acts as a soluble decoy receptor for the receptor activator of nuclear factor κB ligand (RANKL), inhibiting differentiation of osteoclasts. Although the action of osteoprotegerin in blood vessels is not fully understood, its increase has been associated with higher mortality in diabetes, coronary artery disease, acute coronary syndrome, and silent myocardial ischemia. [15] [16] [17] [18] Fetuin A is the main inhibitor of hydroxyapatite formation in the body fluids.
19-21 Wang et al. 21 have shown a 6% lower risk of vascular calcification per 0.01 g/l rise of fetuin A concentration in patients on peritoneal dialysis. Dialyzed patients tend to have decreased levels of fetuin A compared with the group of patients with normal renal function. 2 Fetuin A is postulated to be an independent predictive factor of cardiovascular death, because decreased levels are associated with a significantly shorter survival in dialyzed patients. 19, 21 Arterial calcification, such as osteogenesis, involves a complex interaction of various cells that produce matrix vesicles and subsequent mineralization. Osteocalcin could play a pivotal role both in bone mineralization and vascular calcification.
22
On the other hand, osteocalcin has several hormonal features and is secreted into general circulation from osteoblastic cells. This protein has been associated with high bone turnover and decreased bone mineral density in a variety of clinical settings. Pathological studies in humans showed higher osteocalcin levels in calcified atherosclerotic plaques and calcified cardiac valves than in noncalcified vasculature. 22, 23 Elevated phosphorus and intact parathormone (iPTH) levels in uremic patients contribute to vascular remodeling. The recently discovered FGF-23 is one of the most important regulators of calcium-phosphate metabolism. It is a bone--derived protein that promotes renal phosphorus wasting and inhibits conversion of 25-hydroxyvitamin D to the active 1,25-hydroxyvitamin D form. FGF-23 levels are extremely high in hemodialysis patients and are independently associated with increased mortality in these population. 24, 25 In most hemodialyzed patients, serum FGF-23 concentration is more than 100-fold higher than in controls. 25 osteopontin, and osteoprotegerin. Fetuin A was generally within the reference range, although in most patients it was close to the lower reference limit. FGF-23 levels in our study were higher than those reported in the literature (TAbLE 1) . 13, 24, 25 The relationships between the CCA-IMT and selected bone metabolism markers as well as cardiovascular risk factors were studied using simple correlations as well as a multiple regression. Osteoprotegerin was the only bone marker that significantly correlated with CCA-IMT in a simple analysis (r = 0.38, P = 0.004) (FIGuRE). The CCA-IMT also positively correlated with age (r = 0.54, P <0.0001) and body mass index (BMI) (r = 0.39, P = 0.003). Consistently, in a multiple between the groups were assessed with the analysis of variance and Tuckey post-hoc test. The results were considered statistically significant at a P less than 0.05. The Statistica 9.0 package was used for calculations.
REsuLTs
The clinical and biochemical characteristics of studied patients, including the major cardiovascular risk factors are shown in TAbLE 1. The majority of patients (>80%) had hypertension; about half of the group were diagnosed with left ventricular dysfunction; and about one-third suffered from ischemic heart disease or peripheral artery disease. The majority of patients showed high concentrations of osteocalcin, 30 studied 406 patients with CKD and 58 patients after kidney transplantation without manifestation of cardiovascular disease at the moment of the study. The CCA-IMT was significantly higher in patients with kidney disease compared with the control group (0.9 vs. 0.6 mm) and independently associated with creatinine clearance, mean arterial pressure, and the calcium × phosphorus index. In patients after kidney transplantation, the CCA-IMT considerably decreased reaching the values comparable to controls. Sigrist et al., 15 showed in multiple regression that male patients with osteoprotegerin higher than 25 pmol/l and hypoalbuminemia are at a higher risk of death. Subjects with osteoprotegerin levels lower than 25 pmol/l showed a higher rate of diabetes compared with subjects with osteoprotegerin levels higher than 25 pmol/l. The authors found no association between circulating fetuin A and CRP. These data show that osteoprotegerin is associated with vascular damage independently of CRP. Osteoprotegerin is a specific link between vascular calcification and bone resorption. Nitta et al. 17 showed that high serum osteoprotegerin levels may be independently associated with vascular calcification. Patients with increased aortic calcifications had higher calcium regression model adjusted for the major cardiovascular risk factors, including age, osteoprotegerin (log-transformed), and osteocalcin, were shown to independently predict the CCA-IMT. The inhibitor of extraosseous calcification, fetuin A, did not show a significant association with the CCA-IMT (TAbLE 2) .
CCA-IMT values varied depending on the osteoprotegerin tertile (P = 0.01; FIGuRE). Patients with osteoprotegerin in the upper tertile (>11.90 pmol/l) had a significantly higher CCA-IMT compared with patients in the lower tertile (≤8.44 pmol/l) (0.85 ±0.21 vs. 0.64 ±0.20; P = 0.01). Osteoprotegerin concentrations strongly positively correlated with the duration of dialysis treatment (r = 0.55, P <0.0001). However, the duration of dialysis did not directly correlate with the value of CCA-IMT (r = 0.26, P = 0.06).
dIsCussION The increased concentrations of calcium and phosphorus and insufficiency of natural calcification inhibitors are among the factors leading to the progression of atherosclerotic lesions especially in patients with CKD. 11, 12, 14, 26 Our study focused on the interrelationships between the CCA-IMT and selected biochemical parameters associated with bone metabolism. In patients on peritoneal dialysis, age, log (osteoprotegerin), and osteocalcin were found to be independent risk factors positively associated with the CCA-IMT. Of classic risk factors, age and BMI positively correlated with the CCA-IMT.
Chonchol et al. 6 reported that patients with "subclinical" carotid artery atherosclerosis have a high risk of developing CKD. During a 2-year follow-up, the CCA-IMT presented as an influential, predictive factor of cardiovascular disease when correlated with classic risk factors such as age, sex, cigarette smoking, systolic and diastolic blood pressure, low-density lipoprotein (LDL) cholesterol, and glycated hemoglobin. Increased CCA-IMT was associated with a higher rate of new cases of CKD. In a group of patients of high bone turnover. Osteocalcin can play a pivotal role both in bone mineralization and vascular calcification. The osteoprotegerin / osteocalcin complex may become a useful marker of early development of bone mineral disease and calcification in dialysis patients. Based on the earlier reports and our own results, it appears that an imaging procedure such as the measurement of CCA-IMT should be considered as a routine, noninvasive tool in the evaluation of atherosclerosis at diagnosis of CKD, at initiation of renal replacement therapy, and during treatment.
Elevated serum osteoprotegerin levels could be a biomarker of cardiovascular risk and prognosis in dialyzed patients. High levels of this protein may promote the progression and instability of atherosclerosis.
and CRP levels and lower albumin and iPTH levels compared with patients with a lower degree of calcifications. Patients with increased calcification had higher mean serum levels of osteoprotegerin and osteopontin.
Adamczyk et al. 31 observed that increased serum osteoprotegerin levels and aortic valve calcium score were associated with coronary artery disease in patients with moderate degenerative aortic stenosis. This study showed that enhanced serum osteoprotegerin levels were associated with early valvular calcification.
In our study, in a multiple regression model adjusted for the major cardiovascular risk factors, osteoprotegerin (log-transformed), together with osteocalcin were shown to independently predict the CCA-IMT. Studies suggested that osteoprotegerin may be an inflammatory marker associated with atherosclerosis. The ability of proinflammatory mediators such as tumor necrosis factor α, interleukin 1, and platelet-derived growth factor to enhance osteoprotegerin expression and production in the vascular cells may explain the association of osteoprotegerin concentrations and cardiovascular disease. 18 Osteoprotegerin as a natural decoy receptor for an osteoclast differentiation factor, is produced by osteoblasts in response to PTH. PTH induces the synthesis of RANKL, which in turn plays a pivotal role in osteoclastogenesis by providing an essential signal to osteoclast progenitors through the membrane--anchored receptor activator of nuclear factor κB (RANK). Osteoprotegerin blocks the interaction between RANKL and RANK, inhibits bone resorption, and protects bone tissue against extensive bone deterioration. Increased osteoprotegerin levels in dialysis patients is a reply to high bone resorption, which has a protective function. On the other hand, elevated osteocalcin is a marker 
